Scarica l'app Stockscreener
0.487
0.21%
0.001
Dopo l'orario di chiusura:
.49
0.003
+0.62%
Precedente Chiudi:
$0.486
Aprire:
$0.47
Volume 24 ore:
56,602
Relative Volume:
0.09
Capitalizzazione di mercato:
$16.97M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-6.36%
1M Prestazione:
-30.13%
6M Prestazione:
-54.49%
1 anno Prestazione:
-71.01%
Intervallo 1D:
$0.47
$0.4997
Intervallo di 1 settimana:
$0.4528
$0.5324
Portata 52W:
$0.2026
$4.06
Nkgen Biotech Inc Stock (NKGN) Company Profile
Nome
Nkgen Biotech Inc
Settore
Industria
Telefono
(949) 396-6830
Indirizzo
3001 DAIMLER ST,, SANTA ANA
Confronta NKGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NKGN
Nkgen Biotech Inc
|
0.487 | 16.97M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nkgen Biotech Inc Borsa (NKGN) Ultime notizie
NKGen Biotech (NYSE:NKGN) Trading Up 9.5% – Time to Buy? - Defense World
Midday Stock Roundup: Alignment Healthcare Rises on Update - Orange County Business Journal
Biotech Drama: Compliance Restored! Big Moves by NKGen Biotech! - Jomfruland.net
NKGen Biotech regains compliance with Nasdaq listing standards - Investing.com
NKGen Biotech secures $4.5M in convertible loan agreement - Investing.com India
NKGen Biotech secures $4.5M in convertible loan agreement By Investing.com - Investing.com Canada
NKGen Biotech (NYSE:NKGN) Shares Down 2.3% – Here’s Why - Defense World
Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024 - Asianet Newsable
NKGen Biotech Awards Stock Options to Executives - TipRanks
Head to Head Survey: HilleVax (NASDAQ:HLVX) versus NKGen Biotech (NYSE:NKGN) - Defense World
NKGen Biotech faces Nasdaq delisting over market value By Investing.com - Investing.com Canada
NKGen Biotech faces Nasdaq delisting over market value - Investing.com
NKGen Biotech Selected as Stalking Horse Bidder for NKMax - GlobeNewswire
NKGen Biotech Secures $18M Bid for NKMax Acquisition, Expanding Global IP Rights - StockTitan
NKGen Biotech faces Nasdaq compliance issue By Investing.com - Investing.com Canada
NKGen Biotech faces Nasdaq compliance issue - Investing.com India
NKGen Biotech Receives Notifications From Nasdaq… - Inkl
NKGen Biotech Receives Notifications From Nasdaq Related to - GlobeNewswire
NKGen Biotech Receives Nasdaq Non-Compliance Notice, Granted Extension for Q3 Filing | NKGN Stock News - StockTitan
OC500 2024: Paul Y. Song - Orange County Business Journal
NKGen Biotech (NYSE:NKGN) versus Relay Therapeutics (NASDAQ:RLAY) Financial Contrast - Defense World
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire
NKGen Flat on Presentation of Alzheimer's Treatment - Baystreet.ca
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference - The Manila Times
NKGen Biotech Presents Phase 1/2a Troculeucel Data in - GlobeNewswire
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan
NKGen Biotech avoids Nasdaq delisting with regained compliance - Investing.com India
Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket - Benzinga
Dow Falls Over 100 Points; Netflix Posts Upbeat ResultsCatheter Precision (AMEX:VTAK) - Benzinga
Navigating NKGN Stock: NKGen Biotech Inc Journey - The InvestChronicle
Post-Trade Analysis: NKGen Biotech Inc (NKGN) Slides -6.54, Closing at 0.23 - The Dwinnex
NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024) - The Manila Times
NKGen Biotech undergoes dilutive stock issuance By Investing.com - Investing.com Canada
NKGen Biotech undergoes dilutive stock issuance - Investing.com India
NKGN stock touches 52-week low at $0.35 amid market challenges - Investing.com Australia
NKGen Biotech Announces Poster Presentations at the 17th - GlobeNewswire
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan
Market Watch Highlights: NKGen Biotech Inc (NKGN) Ends on an Upturn Note at 0.40 - The Dwinnex
NKGen Biotech directors resign after a year of service By Investing.com - Investing.com Australia
NKGen Biotech appoints new directors to its board By Investing.com - Investing.com South Africa
NKGen Biotech appoints new directors to its board - Investing.com India
NKGen Biotech Welcomes New Directors and Assigns Committees - TipRanks
Nkgen Biotech Inc Azioni (NKGN) Dati Finanziari
Non sono disponibili dati finanziari per Nkgen Biotech Inc (NKGN). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
5.49%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):